Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryotoxin A is a bufadienolide glycoside primarily isolated from plants of the *Bryophyllum* genus, such as *Bryophyllum tubiflorum*. It belongs to a class of compounds known as cardiac glycosides, which exert their biological effects by inhibiting the Na+/K+-ATPase pump. This inhibition leads to an increase in intracellular sodium and calcium levels, which can cause cardiotoxicity in livestock (a condition known as cotyledonosis). Beyond its toxicological profile, Bryotoxin A and related bufadienolides from *Bryophyllum pinnatum* have been investigated for potential therapeutic applications, including anti-inflammatory, cytotoxic, and anti-atherosclerotic activities. Recent in silico studies suggest that these compounds may target Adenosine Monophosphate-Activated Protein Kinase (AMPK) and Inducible Nitric Oxide Synthase (iNOS) to mitigate the inflammation and vascular thickening associated with atherosclerosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bryotoxin A.